Establishing schedules for repeated doses of strontium and for concurrent chemotherapy in hormone-resistant patients with prostate cancer: measurement of blood and urine strontium levels.

@article{BenYosef2005EstablishingSF,
  title={Establishing schedules for repeated doses of strontium and for concurrent chemotherapy in hormone-resistant patients with prostate cancer: measurement of blood and urine strontium levels.},
  author={Rami Ben-Yosef and Omer Pelled and Rachel Marko and Akiva Vexler and Avi Teshuva and U. R. German and Moshe Levita and Rina Kol},
  journal={American journal of clinical oncology},
  year={2005},
  volume={28 2},
  pages={138-42}
}
Strontium-89 (Sr-89) alone or with concurrent chemotherapy has a role in the treatment of patients with prostate cancer (PCP). The schedules for repeated doses of Sr-89 or for concurrent chemotherapy is undetermined. The objective of this study was to measure the effective half-life (Te) of Sr-89 using a detector available in a nuclear research facility. Blood and urine samples obtained from PCP treated with Sr-89 (Metastron, Amersham, U.K.) were measured for radioactivity with a High Pure… CONTINUE READING